Cannabinoids for Attention Deficit Hyperactivity Disorder (ADHD)

Jordan Tishler

Written by
February 24, 2026

ADHD.jpg

Cannabinoids for Attention Deficit Hyperactivity Disorder (ADHD)

Current scientific evidence on the use of THC and CBD for Attention-Deficit/Hyperactivity Disorder (ADHD) remains limited and inconclusive, with potential for both benefit and harm. The Association of Cannabinoid Specialists recommends that clinicians consider available data and exercise caution, prioritizing established treatments and monitoring for cannabis use disorder when encountering patients with ADHD who use cannabinoids.

ADHD: Epidemiology and Existing Treatments 

Stimulant_Medication.jpg

ADHD is one of the most common neurodevelopmental disorders, affecting both children and adults globally. Symptoms include inattention, impulsivity, and hyperactivity. Effective first-line treatments—such as stimulant and non-stimulant medications, along with behavioral interventions—have a strong clinical evidence base.[1][2] 

THC and Self-Medication in ADHD 

Many individuals with ADHD, especially adults, report self-medicating with cannabis high in THC. Surveys and cohort studies show a higher prevalence of cannabis use disorder in those with ADHD compared to the general population, with risk for developing problematic use estimated to be twice as high. Some patients anecdotally report subjective improvements in anxiety, sleep, or emotional lability when using cannabis, but others experience no benefit or worsening of symptoms.[3][4][5][6] 

A systematic review of observational studies found that daily cannabis users with ADHD often belonged to the hyperactive-impulsive or combined subtypes, which is interpreted as potential evidence for self-medication, though causality remains unproven. Further, high-dose use of phytocannabinoids did appear to be associated in some patients with self-reported reduction in ADHD medication and lower ADHD severity scores; however, these findings are confounded by the lack of placebo control and high risk for bias.[7][8] 

Despite some positive subjective outcomes in case reports and open-label studies, randomized controlled trials (RCTs) using balanced THC:CBD preparations such as Sativex have failed to show statistically significant improvement in ADHD core symptoms. Moreover, concerns remain about adverse effects, including cognitive impairment, risk for cannabis use disorder, lower academic performance, and possible neurodevelopmental vulnerabilities in adolescents.[2][6][9][10] 

CBD and ADHD: Early Clinical Trial Data 

ADHD_brain.jpg

Unlike THC, CBD lacks intoxicating effects and has been explored for a range of neuropsychiatric conditions. In limited, short-term RCTs, CBD has shown marginal positive effects on ADHD symptoms in adults with no negative impacts on cognitive function, particularly when used as an adjunct to established pharmacotherapy and psychotherapy. However, research in children and adolescents is nearly absent, and there is insufficient evidence to extrapolate adult findings to these age groups.  

Studies in children and young people with both ADHD and autism spectrum disorder have assessed CBD for symptoms such as anxiety and irritability, but effects on core ADHD symptoms remain unproven, and these interventions are not considered first-line.[11] 

Complexities of the Endocannabinoid System (ECS) in ADHD 

The ECS plays a modulatory role in executive function, impulsivity, and emotional regulation. Preclinical research and imaging studies reveal structural and functional brain differences in individuals with ADHD who use cannabis, with changes noted in the hippocampus, frontal cortex, and temporal lobes. However, these findings are not yet translatable to clear clinical recommendations and raise additional concerns about the developing brain’s susceptibility to cannabinoids.[12][1][2] 

Potential Harms and Risks 

Cannabis_Use_Disorder.jpg

Individuals with ADHD who use cannabis are at a significantly increased risk for cannabis use disorder, which is associated with functional impairments, academic decline, and complex psychiatric comorbidities.[4][6] 

Clinical Perspective and Recommendations 

From the standpoint of the Association of Cannabinoid Specialists, the use of THC or CBD for ADHD management cannot be recommended as a first- or second-line therapy at this time. While some individual adults may pursue adjunctive use under medical supervision, this should be reserved for cases where evidence-based options have been exhausted, and the patient is fully educated about risks.[13][14][15] 

Best practices include: 

  • Rigorous patient education regarding the lack of established benefit and risk for addiction.[6] 
  • Regular assessment for cannabis use disorder in ADHD populations.[4] 
  • Avoidance of cannabinoids in children and adolescents with ADHD outside of research settings.[11][2] 
  • Use of cannabinoids only in the context of multidisciplinary care and robust informed consent.[16][2] 

Conclusion 

Current evidence does not support recommending THC or CBD as primary or secondary treatments for ADHD. Clinicians should prioritize established therapies, monitor for substance misuse, and counsel patients about the risks associated with cannabis. Further controlled research is urgently needed to define the safety, efficacy, dosing, and appropriate populations for cannabinoid use in ADHD. 

References:

  1. American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). 
  2. Cooper, R. E., Williams, E., Seegobin, S., Tye, C., Kuntsi, J., & Asherson, P. (2017). Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial. European Neuropsychopharmacology, 27(8), 795-808. 
  3. Lisdahl, K. M., Wright, N. E., Kirchner-Medina, C., Maple, K. E., & Shollenbarger, S. (2014). Considering cannabis: The effects of regular cannabis use on neurocognition in adolescents and young adults. Current Addiction Reports, 1(2), 144-156. 
    -[5][8][9][14][15][10][3][1][7][12][16][13][4][2][6][11]
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC10370827/    
  5. https://adc.bmj.com/content/105/Suppl_1/A228.1         
  6. https://www.jeffersonhealth.org/your-health/living-well/exploring-the-role-of-cannabis-in-adhd-management   
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC11032069/     
  8. https://www.verywellmind.com/weed-and-adhd-what-the-research-says-5443195   
  9. https://www.additudemag.com/cannabis-use-disorder-marijuana-adhd/       
  10. https://adai.uw.edu/pubs/pdf/2017mjadhd.pdf   
  11. https://www.cannabisandhealth.org/research/cannabinoid-and-terpenoid-doses-are-associated-with-adult-adhd-status-of-medical-cannabis-patients/   
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC7000160/   
  13. https://www.sciencedirect.com/science/article/pii/S0091305723000941   
  14. https://med.nyu.edu/departments-institutes/child-adolescent-psychiatry/research/neurodevelopmental-autism-spectrum-disorders/cbd-children-autism-adhd-study    
  15. https://onlinelibrary.wiley.com/doi/10.1002/dev.22540   
  16. https://www.verywellhealth.com/does-weed-help-with-adhd-benefits-vs-risks-5210315   
  17. https://chadd.org/attention-article/cbd-oil-for-adhd/   
  18. https://chadd.org/attention-article/adhd-recreational-marijuana/   
  19. https://www.dir.ca.gov/dwc/DWCPropRegs/2025/MTUS-Evidence-Based-Update/Cannabis-Guideline.pdf   
  20. https://www.sciencedirect.com/science/article/abs/pii/S0022395622006549  
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC8832253/  
  22. https://clinicaltrials.gov/study/NCT05219370  
  23. https://www.reddit.com/r/MMA/comments/1dzapbp/position_statement_from_the_association_of/